ATE353361T1 - Gezielten modifikation der chromatinstruktur - Google Patents

Gezielten modifikation der chromatinstruktur

Info

Publication number
ATE353361T1
ATE353361T1 AT01927467T AT01927467T ATE353361T1 AT E353361 T1 ATE353361 T1 AT E353361T1 AT 01927467 T AT01927467 T AT 01927467T AT 01927467 T AT01927467 T AT 01927467T AT E353361 T1 ATE353361 T1 AT E353361T1
Authority
AT
Austria
Prior art keywords
targeted modification
compositions
chromate
methods
chromate structure
Prior art date
Application number
AT01927467T
Other languages
English (en)
Inventor
Alan P Wolffe
Trevor Collingwood
Original Assignee
Sangamo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangamo Biosciences Inc filed Critical Sangamo Biosciences Inc
Application granted granted Critical
Publication of ATE353361T1 publication Critical patent/ATE353361T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/20—Sequence assembly
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ecology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Databases & Information Systems (AREA)
  • Bioethics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
AT01927467T 2000-04-28 2001-04-27 Gezielten modifikation der chromatinstruktur ATE353361T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20059000P 2000-04-28 2000-04-28
US22852300P 2000-08-28 2000-08-28

Publications (1)

Publication Number Publication Date
ATE353361T1 true ATE353361T1 (de) 2007-02-15

Family

ID=26895902

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01927467T ATE353361T1 (de) 2000-04-28 2001-04-27 Gezielten modifikation der chromatinstruktur

Country Status (7)

Country Link
US (4) US7001768B2 (de)
EP (1) EP1276859B1 (de)
AT (1) ATE353361T1 (de)
AU (2) AU2001253914B2 (de)
CA (1) CA2407460C (de)
DE (1) DE60126483T2 (de)
WO (1) WO2001083793A2 (de)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104526A1 (en) * 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
CA2423620A1 (en) 2000-09-28 2002-04-04 Sangamo Biosciences, Inc. Nuclear reprogramming using iwsi and related chromatin remodeling atpases
AU2002213431A1 (en) * 2000-09-29 2002-04-08 Sangamo Biosciences, Inc. Modulation of gene expression using localization domains
US6919204B2 (en) * 2000-09-29 2005-07-19 Sangamo Biosciences, Inc. Modulation of gene expression using localization domains
US7026462B2 (en) 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US6989245B2 (en) * 2001-05-11 2006-01-24 The Burnham Institute Screening, diagnostic and therapeutic methods relating to RIZ
CA2449482A1 (en) * 2001-06-05 2002-12-12 Exelixis, Inc. Chds as modifiers of the p53 pathway and methods of use
EP1409514A4 (de) * 2001-06-22 2005-02-02 Ceres Inc Chimere histon-acetyltransferase-polypeptide
GB0117964D0 (en) * 2001-07-24 2001-09-19 Imp College Innovations Ltd Control of gene expression
EP1435779A4 (de) 2001-09-24 2005-06-01 Sangamo Biosciences Inc Modulation von stammzellen mittels zinkfingerproteinen
US7553667B2 (en) 2002-06-06 2009-06-30 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Regulation of gene expression using chromatin remodelling factors
CA2488697C (en) 2002-06-06 2010-05-25 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Regulation of gene expression using chromatin remodelling factors
US20060166206A1 (en) * 2002-11-15 2006-07-27 Sangamo Biosciences, Inc. Methods and compositions for analysis of regulatory sequences
WO2004050885A2 (en) * 2002-12-05 2004-06-17 Imperial College Innovations Limited Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide
WO2004085644A2 (en) * 2003-03-26 2004-10-07 Basf Plant Science Gmbh Method for producing recombinant organisms
KR20060039019A (ko) 2003-08-08 2006-05-04 상가모 바이오사이언스 인코포레이티드 표적화된 절단과 재조합을 위한 방법 및 그 조성물
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP1678315B1 (de) 2003-09-19 2011-08-03 Sangamo BioSciences, Inc. Gentechnisch hergestellte zinkfingerproteine zur regulation der genexpression
US8039587B2 (en) * 2003-10-24 2011-10-18 Gencia Corporation Methods and compositions for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) * 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US7855824B2 (en) * 2004-03-06 2010-12-21 Qualcomm Mems Technologies, Inc. Method and system for color optimization in a display
ES2527528T3 (es) 2004-04-08 2015-01-26 Sangamo Biosciences, Inc. Métodos y composiciones para modular la contractilidad cardiaca
KR20070060115A (ko) * 2004-09-16 2007-06-12 상가모 바이오사이언스 인코포레이티드 단백질 생산을 위한 조성물 및 방법
CA2599004C (en) 2005-02-28 2015-05-26 Sangamo Biosciences, Inc. Anti-angiogenic methods and compositions
WO2006130201A1 (en) 2005-03-14 2006-12-07 Board Of Regents, The University Of Texas System Antigene oligomers inhibit transcription
JP5066095B2 (ja) 2005-11-17 2012-11-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 染色体ｄｎａに標的化されるオリゴマーによる遺伝子発現の調節
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
GB0607063D0 (en) * 2006-04-07 2006-05-17 Cellcentric Ltd Compositions and methods for epigenetic modification of nucleic acid sequences in vivo
US9428756B2 (en) 2006-08-11 2016-08-30 Dow Agrosciences Llc Zinc finger nuclease-mediated homologous recombination
PT2415872T (pt) 2006-12-14 2016-07-07 Sangamo Biosciences Inc Proteínas com dedos de zinco não canónicas optimizadas
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
US8399218B2 (en) 2007-09-27 2013-03-19 Dow Agrosciences, Llc Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
CN101897033B (zh) 2007-12-17 2012-11-14 高通Mems科技公司 具有干涉式背面掩模的光伏装置及其制造方法
BRPI0821540B1 (pt) * 2007-12-20 2018-07-24 Ethicon, Inc Uso de tecido renal encapsulado em uma esfera de polímero, implante terapêutico e método para produzir o mesmo
US8222221B2 (en) 2008-06-04 2012-07-17 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small RNA targeting of gene promoters
EP2206723A1 (de) 2009-01-12 2010-07-14 Bonas, Ulla Modulare DNA-bindende Domänen
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
AU2010211057B2 (en) * 2009-02-04 2014-12-18 Sangamo Therapeutics, Inc. Methods and compositions for treating neuropathies
US8871905B2 (en) 2009-03-20 2014-10-28 Sangamo Biosciences, Inc. Modification of CXCR4 using engineered zinc finger proteins
WO2010124231A2 (en) 2009-04-24 2010-10-28 The Board Of Regents Of The University Of Texas System Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
JP5866283B2 (ja) * 2009-07-28 2016-02-17 サンガモ バイオサイエンシーズ， インコーポレイテッド トリヌクレオチド反復疾患を治療するための方法および組成物
EP2722392B1 (de) 2009-10-22 2017-11-22 Dow AgroSciences LLC Manipulierte Zinkfingerproteine zur Abzielung auf in Fettsäure-Biosynthese involvierte Pflanzengene
DK2816112T3 (en) 2009-12-10 2018-11-19 Univ Minnesota TAL effector-mediated DNA modification
WO2011146121A1 (en) 2010-05-17 2011-11-24 Sangamo Biosciences, Inc. Novel dna-binding proteins and uses thereof
WO2012097128A1 (en) 2011-01-14 2012-07-19 Two Blades Foundation Citrus trees with resistance to citrus canker
US9499837B2 (en) * 2011-06-21 2016-11-22 E.I. Du Pont De Nemours And Company Methods and compositions for producing male sterile plants
AR087167A1 (es) 2011-07-12 2014-02-26 Two Blades Foundation Genes de resistencia al tizon tardio
AU2012284365B2 (en) 2011-07-15 2017-04-20 The General Hospital Corporation Methods of transcription activator like effector assembly
US10801017B2 (en) * 2011-11-30 2020-10-13 The Broad Institute, Inc. Nucleotide-specific recognition sequences for designer TAL effectors
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
BR112014018294B1 (pt) 2012-01-26 2022-01-11 Norfolk Plant Sciences, Ltd Método para produzir uma planta, cassete de expressão, e, célula bacteriana
US20150045410A1 (en) * 2012-02-06 2015-02-12 University Of Iowa Research Foundation Method of regulating cftr expression and processing
EP2820127B1 (de) * 2012-02-28 2018-09-26 Sigma Aldrich Co. LLC Gezielte histonacetylierung
CN104204225A (zh) 2012-02-29 2014-12-10 桑格摩生物科学股份有限公司 治疗亨廷顿氏病的方法和组合物
EP3597741A1 (de) 2012-04-27 2020-01-22 Duke University Genetische korrektur mutierter gene
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
AU2013272283B2 (en) 2012-06-07 2018-02-15 The Children's Hospital Of Philadelphia Controlled gene expression methods
US20150225734A1 (en) 2012-06-19 2015-08-13 Regents Of The University Of Minnesota Gene targeting in plants using dna viruses
US9597357B2 (en) 2012-10-10 2017-03-21 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
EP2906602B1 (de) * 2012-10-12 2019-01-16 The General Hospital Corporation Transkriptionsaktivator-like-effektor-lysinspezifische demethylase-1 (lsd1)-fusionsproteine
CN104968193B (zh) 2012-11-01 2021-02-09 塞尔克蒂斯股份有限公司 用于生成治疗性蛋白质的植物
US10415024B2 (en) 2012-11-16 2019-09-17 Poseida Therapeutics, Inc. Site-specific enzymes and methods of use
PL2934097T3 (pl) 2012-12-21 2018-11-30 Cellectis Ziemniaki o ograniczonej słodkości indukowanej chłodem
WO2014124284A1 (en) 2013-02-07 2014-08-14 The General Hospital Corporation Tale transcriptional activators
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
CN105408483A (zh) 2013-03-15 2016-03-16 通用医疗公司 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向
US10113162B2 (en) 2013-03-15 2018-10-30 Cellectis Modifying soybean oil composition through targeted knockout of the FAD2-1A/1B genes
WO2014204578A1 (en) 2013-06-21 2014-12-24 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
US9828582B2 (en) * 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
EP4372090A3 (de) 2013-11-07 2024-08-07 Editas Medicine, Inc. Crispr-assoziierte verfahren und zusammensetzungen mit regelnden grnas
WO2015070212A1 (en) 2013-11-11 2015-05-14 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
WO2015116680A1 (en) 2014-01-30 2015-08-06 Two Blades Foundation Plants with enhanced resistance to phytophthora
AU2015231353B2 (en) 2014-03-18 2020-11-05 Sangamo Therapeutics, Inc. Methods and compositions for regulation of zinc finger protein expression
US9522936B2 (en) 2014-04-24 2016-12-20 Sangamo Biosciences, Inc. Engineered transcription activator like effector (TALE) proteins
WO2015171603A1 (en) 2014-05-06 2015-11-12 Two Blades Foundation Methods for producing plants with enhanced resistance to oomycete pathogens
EP3158072B1 (de) 2014-06-20 2021-01-13 Cellectis Kartoffeln mit reduzierter granule-bound-starch-synthase
GB201418965D0 (de) * 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
EP3754027A1 (de) * 2014-12-01 2020-12-23 The Broad Institute, Inc. Verfahren zur in-situ-bestimmung der nähe von nukleinsäuren
EP3256487A4 (de) 2015-02-09 2018-07-18 Duke University Zusammensetzungen und verfahren zur epigenombearbeitung
US11697820B2 (en) 2015-05-09 2023-07-11 Two Blades Foundation Late blight resistance gene from Solanum americanum and methods of use
AU2016278226B2 (en) 2015-06-17 2021-08-12 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US10837024B2 (en) 2015-09-17 2020-11-17 Cellectis Modifying messenger RNA stability in plant transformations
WO2017062790A1 (en) 2015-10-09 2017-04-13 Two Blades Foundation Cold shock protein receptors and methods of use
EP4089175A1 (de) 2015-10-13 2022-11-16 Duke University Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
EA201891317A3 (ru) 2015-11-30 2019-04-30 Дьюк Юниверсити Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
SG11201805157TA (en) 2015-12-18 2018-07-30 Sangamo Therapeutics Inc Targeted disruption of the mhc cell receptor
CN108778297B (zh) 2015-12-18 2024-02-09 桑格摩生物治疗股份有限公司 T细胞受体的靶向破坏
ES3039237T3 (en) 2016-02-02 2025-10-20 Cellectis Modifying soybean oil composition through targeted knockout of the fad3a/b/c genes
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
WO2018017754A1 (en) 2016-07-19 2018-01-25 Duke University Therapeutic applications of cpf1-based genome editing
KR20220145913A (ko) 2016-08-24 2022-10-31 상가모 테라퓨틱스, 인코포레이티드 가공된 표적 특이적 뉴클레아제
EP3509645A4 (de) 2016-09-07 2020-06-17 Sangamo Therapeutics, Inc. Modulation von lebergenen
UY37482A (es) 2016-11-16 2018-05-31 Cellectis Métodos para alterar el contenido de aminoácidos en plantas mediante mutaciones de desplazamiento de marco
WO2018112356A1 (en) 2016-12-16 2018-06-21 Two Blades Foundation Late blight resistance genes and methods of use
AU2018260469B2 (en) 2017-04-25 2024-09-05 Cellectis Alfalfa with reduced lignin composition
WO2018200943A1 (en) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3619322A4 (de) 2017-05-03 2021-06-30 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur modifizierung eines mukoviszidose-transmembranleitungsregulator (cftr)-gens
WO2018209209A1 (en) 2017-05-12 2018-11-15 Two Blades Foundation Methods for screening proteins for pattern recognition receptor function in plant protoplasts
CN111542608A (zh) 2017-07-28 2020-08-14 双刃基金会 马铃薯y病毒抗性基因及使用方法
AU2018313167A1 (en) 2017-08-08 2020-02-27 Sangamo Therapeutics, Inc. Chimeric antigen receptor mediated cell targeting
WO2019108619A1 (en) 2017-11-28 2019-06-06 Two Blades Foundation Methods and compositions for enhancing the disease resistance of plants
AU2018375192B2 (en) 2017-12-01 2023-11-09 Encoded Therapeutics, Inc. Engineered DNA binding proteins
WO2019126578A1 (en) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
EP3737226A1 (de) 2018-01-12 2020-11-18 Two Blades Foundation Stammrostresistenzgene und verfahren zur verwendung
EP3740580A4 (de) 2018-01-19 2021-10-20 Duke University Genom-engineering mit crispr-cas-systemen bei eukaryonten
JP7332622B2 (ja) 2018-04-18 2023-08-23 サンガモ セラピューティクス， インコーポレイテッド ハンチンチン（ｈｔｔ）の調節のためのジンクフィンガータンパク質組成物
JP7555822B2 (ja) 2018-04-19 2024-09-25 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア ゲノム編集のための組成物および方法
KR102712986B1 (ko) 2018-08-23 2024-10-07 상가모 테라퓨틱스, 인코포레이티드 조작된 표적 특이적 염기 편집기
US20210317430A1 (en) 2018-09-18 2021-10-14 Sangamo Therapeutics, Inc. Programmed cell death 1 (pd1) specific nucleases
CA3113449A1 (en) 2018-09-21 2020-03-26 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
AU2019361129A1 (en) 2018-10-18 2021-05-20 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
JP7523449B2 (ja) 2019-01-11 2024-07-26 アクイタス セラピューティクス インコーポレイテッド 活性剤の脂質ナノ粒子送達のための脂質
BR112021024055A2 (pt) 2019-05-29 2022-02-08 Encoded Therapeutics Inc Composições e métodos para a regulação seletiva de gene
BR112021026248A2 (pt) 2019-06-27 2022-03-03 Two Blades Found Molécula de ácido nucleico isolada que codifica uma proteína atrlp23 engenheirada, proteína atrlp23 engenheirada, cassete de expressão, vetor, célula hospedeira, planta ou célula vegetal, métodos para fazer uma proteína atrlp23 engenheirada, para fazer uma molécula de ácido nucleico que codifica uma proteína atrlp23 engenheirada e para intensificar a resistência de uma planta
WO2021011348A1 (en) 2019-07-12 2021-01-21 The Regents Of The University Of California Plants with enhanced resistance to bacterial pathogens
US20230159927A1 (en) * 2020-05-08 2023-05-25 Duke University Chromatin remodelers to enhance targeted gene activation
BR112023000327A2 (pt) 2020-07-16 2023-01-31 Acuitas Therapeutics Inc Lipídeos catiônicos para o uso em nanopartículas lipídicas
WO2022046760A2 (en) 2020-08-25 2022-03-03 Kite Pharma, Inc. T cells with improved functionality
US20240218356A1 (en) 2021-05-11 2024-07-04 Two Blades Foundation Methods for preparing a library of plant disease resistance genes for functional testing for disease resistance
AU2022349627A1 (en) 2021-09-21 2024-03-21 Scribe Therapeutics Inc. Engineered casx repressor systems
WO2023056269A1 (en) 2021-09-30 2023-04-06 Two Blades Foundation Plant disease resistance genes against stem rust and methods of use
IL313486A (en) 2021-12-16 2024-08-01 Acuitas Therapeutics Inc Lipids for use in lipid nanoparticle formulations
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
KR20250044484A (ko) 2022-06-24 2025-03-31 튠 쎄라퓨틱스, 인코포레이티드 표적 유전자 억제를 통해 저밀도 지단백질을 감소시키기 위한 조성물, 시스템, 및 방법
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
AR133243A1 (es) 2023-07-14 2025-09-10 Two Blades Found Métodos para mejorar la termoestabilidad de los receptores inmunitarios de plantas
WO2025019221A1 (en) 2023-07-15 2025-01-23 Two Blades Foundation Broad-spectrum polerovirus resistance gene
AU2024335327A1 (en) 2023-09-01 2026-03-26 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436150A (en) * 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
AU7378196A (en) * 1995-09-28 1997-04-17 Trustees Of Columbia University In The City Of New York, The Chimeric dna-binding/dna methyltransferase nucleic acid and polypeptide and uses thereof
JP2850816B2 (ja) * 1995-12-18 1999-01-27 日本電気株式会社 バンプ接合検査装置及び検査方法
US6015709A (en) * 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
US5972608A (en) * 1997-08-27 1999-10-26 University Of Massachusetts Assays and reagents for chromatin remodeling enzymes and their modulators
US6153383A (en) * 1997-12-09 2000-11-28 Verdine; Gregory L. Synthetic transcriptional modulators and uses thereof
AU746454B2 (en) * 1998-03-02 2002-05-02 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US20020188103A1 (en) * 1998-10-09 2002-12-12 Timothy H. Bestor Chimeric dna-binding/dna methyltransferase nucleic acid and polypeptide and uses thereof
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) * 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
EP1276869A2 (de) * 2000-01-21 2003-01-22 The Scripps Research Institute Methoden und zusammensetzungen zur expressionsmodulierung in pflanzen
KR20020086508A (ko) * 2000-02-08 2002-11-18 상가모 바이오사이언스 인코포레이티드 약물 발견용 세포
US7205103B2 (en) 2000-02-11 2007-04-17 The Salk Institute For Biological Studies Method of regulating transcription in a cell
WO2001068807A2 (en) * 2000-03-16 2001-09-20 Fred Hutchinson Cancer Research Center Identification of in vivo dna binding loci of chromatin proteins using a tethered nucleotide modification enzyme

Also Published As

Publication number Publication date
US20100323424A1 (en) 2010-12-23
EP1276859B1 (de) 2007-02-07
US20060188972A1 (en) 2006-08-24
US8071370B2 (en) 2011-12-06
DE60126483T2 (de) 2007-12-06
WO2001083793A2 (en) 2001-11-08
CA2407460C (en) 2013-06-25
US7001768B2 (en) 2006-02-21
US7785792B2 (en) 2010-08-31
DE60126483D1 (de) 2007-03-22
EP1276859A2 (de) 2003-01-22
US20090023153A1 (en) 2009-01-22
CA2407460A1 (en) 2001-11-08
AU5391401A (en) 2001-11-12
US20020115215A1 (en) 2002-08-22
AU2001253914B2 (en) 2006-06-08
WO2001083793A3 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
ATE353361T1 (de) Gezielten modifikation der chromatinstruktur
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
PT1411908E (pt) Tratamento de infeccoes da unha com no
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
WO2003082186A3 (en) Use of benzimidazole analogs in the treatment of cell proliferation
CY1117027T1 (el) Συνεργιστικοι μυκητοκτονοι συνδυασμοι δραστικων ουσιων
ATE495162T1 (de) Azabicyclo-octan und nonan derivate mit ddp-iv hemmender wirkung
ES2721631T3 (es) Método para aislar pequeñas moléculas de ARN
MXPA04000622A (es) Pirazolilcarboxanilidas como funguicidas.
WO2002013833A3 (en) SMALL MOLECULE INHIBITORS TARGETED AT Bcl-2
TW200513461A (en) Organische verbindungen
DK1266011T3 (da) Svampetranskriptionsaktivator, der er anvendelig i fremgangsmåder til fremstilling af polypeptider
ATE469911T1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
CY1108549T1 (el) Συνθετικες μεθοδοι για απλιδινη και νεα κατα του ογκου παραγωγα, μεθοδοι κατασκευης και χρησης αυτων
TW200500339A (en) Pyrrolidine derivatives, and process for the preparation
DE602004029602D1 (de) Brennstoffzelle, auseinanderbauverfahren dafür und darin verwendete trennglieder
MXPA06002349A (es) Derivados de aminopropanol.
WO2001083751A3 (en) Methods for binding an exogenous molecule to cellular chromatin
DK1311670T3 (da) Fremgangsmåde til massiv dirigeret mutagenese
MX2007010045A (es) Pirazolopirimidinas.
WO2002030465A3 (en) Compositions that inhibit proliferation of cancer cells
AU2001269575A1 (en) Nucleic acid sequences and proteins involved in cellular senescence
NO20062978L (no) Reduksjon av dermal arrdannelse
GB0324210D0 (en) Organic compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties